Marginally failed study for Europe [Study As­sess­ment]

posted by balakotu – India, 2018-04-24 09:30 (2185 d 17:37 ago) – Posting: # 18726
Views: 4,081

Hi,
I have conducted a full replicate BE study for one of the highly variable product for Europe regulatory.
Based on the reference product variability, relaxed 90% Confidence Intervals is 75.18 to 133.01 for Cmax.
Study marginally failed with 90% upper CI data of 133.18
Is there any way to justify Europe regulatory authority(ies) to accept this study data? (DCP submission)

Regards


Edit: Category changed; see also this post #1 and #4. [Helmut]

Complete thread:

UA Flag
Activity
 Admin contact
22,986 posts in 4,823 threads, 1,657 registered users;
59 visitors (0 registered, 59 guests [including 5 identified bots]).
Forum time: 03:08 CEST (Europe/Vienna)

Art is “I”; science is “we”.    Claude Bernard

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5